Samara Mhana, Hussein Said, Afraa Zrieki
Samara Mhana1*, Hussein Said2, Afraa Zrieki3
1Biochemistry and Microbiology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria.
2Internal Medicine Department, Faculty of Medicine, Tishreen University, Lattakia, Syria.
3Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Tishreen University, Lattakia, Syria.
Volume - 16,
Issue - 1,
Year - 2023
Chronic kidney disease (CKD) is associated with high morbidity and increased cardiovascular mortality. Chronic in?ammation was found to be correlated with cardiovascular disease (CVD) in CKD population. High-sensitivity C-reactive protein (hs-CRP), is one of biomarkers of subclinical inflammation, and widely used as an independent predictor of cardiovascular risk. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were introduced as potential markers for evaluation of in?ammation in several diseases. However, there are a few studies in CKD patients. We aimed to evaluate the relationship of NLR and PLR with hs-CRP levels in Syrian patients with CKD. The study included 100 CKD patients in stages 3 to 5 seen at Tishreen University Hospital, and 22 subjects served as control. CKD patients were divided into two groups, according to the presence or absence of in?ammation, based on the high-sensitivity C-reactive protein (hs-CRP) cut off value of 3 mg/l. Blood samples were collected for blood count and hs-CRP levels determination. hs-CRP concentration was measured by immunoturbidimetry assay kit. NLR and PLR were calculated based on the absolute number of neutrophils, lymphocytes and platelets. We used the SPSS 25.0 program for the statistical analysis. Probability (P) value<0.05 was considered statistically significant. NLR as well as PLR and hs-CRP levels were significantly higher in all CKD groups compared to control subjects (p<0.05, for all). NLR and PLR values were significantly di?erent between CKD groups with and without in?ammation (for both, p<0.001). Both NLR and PLR were positively correlated with hs-CRP (r=0.50, p<0.001 for NLR; r=0.43, p<0.001 for PLR) in CKD patients. The best cuto? point for NLR to detect in?ammation was =3.06, with 70% sensitivity and 81.1% speci?city. For PLR, the cut off was =144.78, with 59% sensitivity and 73% speci?city. There was no signi?cant di?erence between the area under the NLR and PLR curve (0.77 vs. 0.70, p=0.19) for this population. Our findings suggests that NLR and PLR are available, simple and less expensive methods that could be used as markers of inflammation in CKD patients instead of hs-CRP.
Cite this article:
Samara Mhana, Hussein Said, Afraa Zrieki. NLR and PLR as Available and Inexpensive markers for Evaluation of Subclinical Inflammation in patients with Chronic Kidney Disease. Research Journal of Pharmacy and Technology 2023; 16(1):187-2. doi: 10.52711/0974-360X.2023.00035
Samara Mhana, Hussein Said, Afraa Zrieki. NLR and PLR as Available and Inexpensive markers for Evaluation of Subclinical Inflammation in patients with Chronic Kidney Disease. Research Journal of Pharmacy and Technology 2023; 16(1):187-2. doi: 10.52711/0974-360X.2023.00035 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-1-35
1. Dhivya K, et al. Prognostic Potential of Serum Biomarkers as Predictors for Cardiovascular Complications and Disease Progression in Chronic Kidney Disease Patients. Research Journal of Pharmacy and Technology. 2016; 9(3): 227-234. doi: 10.5958/0974-360X.2016.00041.X
2. Thomas A, et al. Assessment of acute complications and quality of life in hemodialysis patients with chronic kidney disease. Research Journal of Pharmacy and Technology. 2021; 14(5): 2671-2675. doi: 10.52711/0974-360X.2021.00471
3. Al-Baghdadi D D H, et al. Quality of life for hemodialysis patients with chronic renal failure. Research Journal of Pharmacy and Technology. 2018; 11(6): 2398-2403. doi: 10.5958/0974-360X.2018.00443.2
4. Maheswari C, et al. Green tea (cardiac tea) vs java tea (kidney tea): A review. Research Journal of Pharmacy and Technology. 2015; 8(1): 94-100.
5. Johnston N, et al. Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease: Ischaemic heart disease. Heart (British Cardiac Society). 2008; 94(8): 1080-1088. doi: 10.1136/hrt.2007.136739
6. Vanmathi S M, et al. A Pathophysiological Approach of Macrovascular Complication in Diabetes Mellitus with Hypertension: A Systematic Review. Research Journal of Pharmacy and Technology. 2019; 12(2): 901-906. doi: 10.5958/0974-360X.2019.00154.9
7. Stenvinkel P, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clinical journal of the American Society of Nephrology: CJASN. 2008; 3(2): 505-521. doi: 10.2215/CJN.03670807
8. Derouiche S, et al. Heavy metals, oxidative stress and inflammation in pathophysiology of chronic kidney disease-a review. Asian Journal of Pharmacy and Technology. 2020; 10(3): 202-206. doi: 10.5958/2231-5713.2020.00033.1
9. Dungey M, et al. Inflammatory factors and exercise in chronic kidney disease. International Journal of Endocrinology. 2013; 2013. https://doi.org/10.1155/2013/569831
10. Brito G, et al. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Nondialysis Chronic Kidney Patients. International Journal of Inflammation. 2021; 2021. https://doi.org/10.1155/2021/6678960
11. Turkmen K, et al. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Renal failure. 2012; 34(2): 155-159. doi:10.3109/0886022X.2011.641514
12. Valga F, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as biological markers of interest in kidney disease. Nefrologia. 2019; 39(3): 243-249. doi: 10.1016/j.nefro.2018.11.005
13. Ridker, et al. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3): 363-369. doi: 10.1161/01.cir.0000053730.47739.3c
14. Ganapathi A, et al. Estimation of C-Reactive Protein in Cardiovascular Disease Patients. Research Journal of Pharmacy and technology. 2018; 11(8): 3303-3307. doi: 10.5958/0974-360X.2018.00607.8
15. Mounika, et al. Periodontitis as a risk factor of atherosclerosis. Research Journal of Pharmacy and Technology. 2016; 9(11): 2017-2019.
16. Faria SS, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016; 10: 702. doi: 10.3332/ecancer.2016.702
17. Mallappa S, et al. Preoperative neutrophil to lymphocyte ratio> 5 is a prognostic factor for recurrent colorectal cancer. Colorectal disease. 2013; 15(3): 323-328. doi: 10.1111/codi.12008
18. Templeton A J, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention. 2014; 23(7): 1204-1212. doi: 10.1158/1055-9965.EPI-14-0146
19. Larmann J, et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery. BMC cardiovascular disorders. 2020; 20(1): 1-9. doi: 10.1186/s12872-020-01500-6
20. Wang S, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are effective predictors of prognosis in patients with acute mesenteric arterial embolism and thrombosis. Annals of vascular surgery. 2018; 49: 115-122. doi: 10.1016/j.avsg.2018.01.059
21. Mertoglu C, et al. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes & metabolic syndrome. 2017; 11: S127-S131. doi: 10.1016/j.dsx.2016.12.021
22. Wang J R, et al. Association between neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and diabetic retinopathy among diabetic patients without a related family history. Diabetology & Metabolic Syndrome. 2020; 12(1): 1-10. https://doi.org/10.1186/s13098-020-00562-y
23. Kocyigit I, et al. Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. Journal of nephrology. 2013; 26(2): 358-365. doi: 10.5301/jn.5000152
24. Catabay C, et al. Lymphocyte cell ratios and mortality among incident hemodialysis patients. American Journal of Nephrology. 2017; 46(5): 408-416. doi: 10.1159/000484177
25. Ahbap E, et al. Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease. Clinical nephrology. 2016; 85(4): 199-208. doi: 10.5414/CN108584
26. Joudah M T, et al. Biochemical Investigation to Determine the Factors Involved in Renal Failure Formation for Dialysis Patients. Research Journal of Pharmacy and Technology. 2021; 14(12): 6275-6280. doi: 10.52711/0974-360X.2021.01085
27. Li P, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD). BMC Nephrology. 2020; 21(1): 1-8. https://doi.org/10.1186/s12882-020-02174-0
28. Levey A S, et al. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. American Journal of Kidney Diseases. 2010; 55(4): 622-627. doi: 10.1053/j.ajkd.2010.02.337
29. Jaaban M, et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as novel risk markers for diabetic nephropathy in patients with type 2 diabetes. Heliyon. 2021; 7(7): e07564. doi: 10.1016/j.heliyon.2021.e07564
30. Goyal S, et al. Vascular Endothelial Dysfunction: Complication of Diabetes Mellitus and Hyperhomocysteinemia. Research Journal of Pharmacy and Technology. 2010; 3(3): 657-664.
31. Chopade A R, et al. Evaluation of membrane stabilizing and inhibition of protein denaturation activity of Phyllanthus fraternus Webster. Research Journal of Pharmacy and Technology. 2013; 6(3): 251-254.
32. Zhao W M, et al. Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Renal failure. 2020; 42(1): 1059-1066. doi: 10.1080/0886022X.2020.1832521
33. Okyay G U, et al. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Renal failure. 2013; 35(1): 29-36. doi: 10.3109/0886022X.2012.734429
34. Valencia V C, et al. Inflammation in hemodialysis and their correlation with neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Nefrologia. 2017; 37(5): 554-556. doi: 10.1016/j.nefroe.2016.12.014
35. Turkmen K, et al. Platelet‐to‐lymphocyte ratio better predicts inflammation than neutrophil‐to‐lymphocyte ratio in end‐stage renal disease patients. Hemodialysis international. 2013; 17(3): 391-396. doi: 10.1111/hdi.12040
36. Malhotra R., et al. Relationship of neutrophil-to-lymphocyte ratio and serum albumin levels with C-reactive protein in hemodialysis patients: results from 2 international cohort studies. Nephron. 2015; 130(4): 263-270. doi: 10.1159/000437005
37. Shaarawy A, et al. Neutrophils to lymphocytes ratio is an easy non expensive marker of inflammation in hemodialysis patients. Journal of Clinical & Experimental Nephrology. 2018; 3(4): 19. doi: 10.21767/2472-5056.100070